Cell Therapy News Volume 14.39 | Oct 7 2013

    0
    39
    Cell Therapy News - Your Industry in an Instant
    Your Industry in an InstantTwitter Facebook
    Publications | Reviews | Policy | Business | NIH | Events | Jobs

     
    TOP STORY
    Functional Salivary Gland Regeneration by Transplantation of a Bioengineered Organ Germ
    Scientists demonstrated the full functional regeneration of a salivary gland that reproduces the morphogenesis induced by reciprocal epithelial and mesenchymal interactions through the orthotopic transplantation of a bioengineered salivary gland germ as a regenerative organ replacement therapy. [Nat Commun]
    Full Article | Press Release
    Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Functional Lacrimal Gland Regeneration by Transplantation of a Bioengineered Organ Germ
    Researchers demonstrated orthotopic transplantation of bioengineered lacrimal gland germs into adult mice with an extra-orbital lacrimal gland defect, a mouse model that mimics the corneal epithelial damage caused by lacrimal gland dysfunction. [Nat Commun] Full Article | Press Release

    Integration of a Calcined Bovine Bone and BMSC-Sheet 3D Scaffold and the Promotion of Bone Regeneration in Large Defects
    Researchers investigated the feasibility of applying calcined bovine bone, which was coated by allograft bone marrow mesenchymal stem cells (BMSC)-sheet, as a 3D scaffold material in bone repairing tissue engineering. [Biomaterials] Abstract

    Autologous Tenocyte Injection for the Treatment of Severe, Chronic Resistant Lateral Epicondylitis: A Pilot Study
    On the basis of positive outcomes from preclinical studies, this study is the first clinical trial of autologous tenocyte injection on severe tendinopathy associated with chronic lateral epicondylitis. [Am J Sports Med]
    Abstract | Press Release

    Human Endometrial Mesenchymal Stem Cells Modulate the Tissue Response and Mechanical Behavior of Polyamide Mesh Implants for Pelvic Organ Prolapse Repair
    Investigators used a tissue engineering approach to assess the in vivo biological and biomechanical behavior of a new gelatin/polyamide mesh, seeded with a novel source of mesenchymal stem cells in a subcutaneous rat model of wound repair. [Tissue Eng Part A] Abstract

    Boosting Angiogenesis and Functional Vascularization in Injectable Dextran-Hyaluronic Acid Hydrogels by Endothelial-Like Mesenchymal Stromal Cells
    Researchers examined in vitro the reciprocal influences between cells and matrix. Dextran-hyaluronic acid hydrogels (Dex-g-HA) enabled higher endothelial-like cells derived from mesenchymal stromal cell (EL-MSC) metabolic rates associated with optimal cell sprouting in vitro, compared to HUVECs. In vivo evaluation demonstrated absence of an acute inflammatory response and EL-MSCs incorporated within Dex-g-HA formed a functional vascular network integrated with the host vascular system. [Tissue Eng Part A] Abstract

    Stem Cell-Like Dog Placenta Cells Afford Neuroprotection against Ischemic Stroke Model via Heat Shock Protein Upregulation
    Scientists investigated the dog placenta as a viable source of stem cells for stroke therapy. Immunocytochemical evaluation of phenotypic markers of dog placenta cells (DPCs) cultured in proliferation and differentiation medium revealed that DPCs expressed both stem cell and neural cell markers, respectively. [PLoS One] Full Article

    Impact of Failed Response to Novel Agent Induction in Autologous Stem Cell Transplantation for Multiple Myeloma
    Investigators evaluated the impact of the response to induction therapy on the long-term prognosis of multiple myeloma (MM) after autologous stem cell transplantation (ASCT) in the era of novel agents. A total of 171 patients who were newly diagnosed with MM and underwent early ASCT were analyzed. [Ann Hematol] Abstract

    Activation of Human Mesenchymal Stem Cells Impacts Their Therapeutic Abilities in Lung Injury by Increasing Interleukin (IL)-10 and IL-1RN Levels
    Investigators injected endotoxemic mice with minimally manipulated human mesenchymal stem cells isolated from the bone marrow of vertebral bodies with or without prior activation with serum from acute respiratory distress syndrome patients. [Stem Cells Transpl Med] Abstract

    Read White Paper - STEMSOFT Software Inc.: Your Inspection Workhorse.

     
    REVIEWS
    Cell Therapy for Multiple Sclerosis: An Evolving Concept with Implications for Other Neurodegenerative Diseases
    Efforts to develop stem-cell therapies for multiple sclerosis have been conventionally built on the principle of direct implantation of cells to replace oligodendrocytes, and therefore to regenerate myelin. Recent progress in understanding of disease processes in multiple sclerosis include observations that spontaneous myelin repair is far more widespread and successful than was previously believed, that loss of axons and neurons is more closely associated with progressive disability than is myelin loss, and that damage occurs diffusely throughout the CNS in gray and white matter, not just in discrete, isolated patches or lesions. [The Lancet]
    Abstract | Press Release

    Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field.

    New EasySepâ„¢ 15-Minute Mouse Cell Isolation Kits - Calculate Time Savings

     
    POLICY
    Tales From the Shutdown: ClinicalTrials.gov Gets Exemption
    A plea from a federal lawmaker has allowed the National Institutes of Health to update a clinical trials database that had been frozen as a result of the U.S. government shutdown, according to The Boston Globe. [ScienceInsider] Editorial

    U.S. Senate Blocks House Plan to Exempt NIH From Shutdown
    The top Democrat in the U.S. Senate has blocked a House of Representatives plan to restore current funding levels for the National Institutes of Health (NIH) through 15 December, saying House Republicans shouldn’t be allowed to pick and choose which federal agencies they’d like to reopen. [ScienceInsider] Editorial

    New HHS Rule: Blood Stem Cells Aren’t for Sale
    The Department of Health and Human Services has issued a proposed rule that would include hematopoietic stem cells acquired by apheresis under the definition of “human organ,” precluding payment for them. [MedPage Today, LLC] Editorial

    Call for Change to Stem Cell Regulation
    Professor Wilmut is among a number of leading scientists calling on governments from around the world to adopt a joined-up approach. This would allow induced pluripotent stem cells to be shared between countries. [The University of Edinburgh] Press Release

    Enter Our Contest 
    Cell Therapy News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.

     
    BUSINESS
    Researchers at University of Coimbra, Portugal, Win the Astellas European Foundation’s Inaugural Uro-Oncology Grant
    The Astellas European Foundation announced that Dr. Celia Gomes from the University of Coimbra has been selected as the recipient of the inaugural Uro-Oncology Grant 2013. The $150,000 award will support the University of Coimbra’s team looking at natural killer cell-based adoptive therapy targeting human bladder cancer stem cells: impact on tumor progression using a humanized orthotopic animal model. [PR Newswire Association LLC] Press Release

    TrakCel Accelerates Stem Cell Logistics Solution Development with Welsh Government Funding
    TrakCel has announced it will commence trials with leading international pharmaceutical company GlaxoSmithKline in early 2014. Benefiting from an initial £100,000 from the Welsh Government SMART Cymru award for Research Development and Innovation, TrakCel has been able to swiftly develop demonstrable initial technology and present it to key players in the industry including GlaxoSmithKline. [Biotec Services International] Press Release

    StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury
    StemCells, Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary HuCNS-SC® human neural stem cells as a treatment for spinal cord injury. [StemCells, Inc.] Press Release

    BrainStorm Launches US Activities for Its Multi-Center ALS Clinical Trial
    BrainStorm Cell Therapeutics announced that it has launched its activities in the US in preparation for its Phase IIa multi-center clinical trial, with the initiation of the NurOwnâ„¢ technology transfer process at the Dana Farber Cancer Institute. [BrainStorm Cell Therapeutics, Inc.] Press Release

    Nanoparticle Stem Cell Replacement Therapy for Reflux Nephropathy
    An EU-funded project has investigated the potential of stem cell-based replacement therapy for prevention of end stage renal disease. The work involved the design of a new type of magnetic nanoparticle to label the stem cells for in vivo tracking. [Nanowerk] Press Release

    Cellular Dynamics Issued U.S. Patent Covering iPSC Episomal Reprogramming
    Cellular Dynamics International announced that the U.S. Patent and Trademark Office issued Patent No. 8,546,140 entitled “Methods for the Production of iPS Cells Using Non-Viral Approach”. The newly issued patent relates to the method by which adult tissue cells, such as blood or skin, are reprogrammed into induced pluripotent stem (iPS) cells by the insertion of episomal vectors. [Cellular Dynamics International] Press Release

    Bone Therapeutics Receives Clearance for ALLOB® Phase I/IIa Trial
    Bone Therapeutics announced that it has received clearance from the Competent Authorities in Belgium and the UK for a Phase I/IIa trial with its allogeneic cell therapy product ALLOB® for the treatment of delayed union fractures. [Bone Therapeutics S.A.] Press Release

    Medistem Announces Preclinical Data on Type 1 Diabetes and Filing of Intellectual Property
    Medistem, Inc. announced that it filed patent application #61/885909 covering immune modulatory aspects of ERC-124, the company’s clinical-stage stem cell product. The provisional patent titled, “TOLEROGENIC USES OF ENDOMETRIAL REGENERATIVE CELLS“, was invented by Thomas Ichim, Ph.D. and Hugh Taylor, M.D. [GlobeNewswire, Inc.] Press Release

    Geron Completes Divestiture of Stem Cell Assets
    Geron Corporation announced the closing of the transaction to divest the company’s stem cell assets. Geron entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc. [Geron Corporation] Press Release

    From our sponsor:
    Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

     
    NIH
    Center for Scientific Review; Notice of Closed Meeting

     
    EVENTS
    NEW Cell Culture World Congress 2014
    February 25-27, 2014
    Munich, Germany

    NEW 9th Annual World Stem Cells & Regenerative Medicine Congress 2014
    May 20-22, 2014
    London, United Kingdom

    Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.

     
    JOB OPPORTUNITIES
    NEW Assistant Professorships – Stem Cells and Regenerative Medicine (Keck School of Medicine)

    Postdoctoral Research Fellow – Stem Cells (Bioprocessing Technology Institute)

    Postdoctoral Research Fellow – Human Induced Pluripotent Stem Cell Research (Bioprocessing Technology Institute)

    Manufacturing Manager (StemCells Inc.)

    Process Development Manager (StemCells Inc.)

    Manufacturing Associate (StemCells Inc.)

    Research Scientist – Stem Cell Research (Approach People Recruitment)

    Postdoctoral Position – Development of Cell Delivery Systems in Bone Repair (Fujifilm)

    Postdoctoral Fellow – Stem Cell Research (Tsinghua University Graduate School at Shenzhen)

    Postdoctoral Position – Leukemia Biology (Northwestern University)

    Cellular Therapy Lab Specialist (University of Texas Medical School at Houston)

    Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

    Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

    Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

    Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

    Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

    Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.